Format

Send to

Choose Destination
Antiviral Res. 2014 Jun;106:111-5. doi: 10.1016/j.antiviral.2014.03.017. Epub 2014 Apr 6.

Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.

Author information

1
INRS-Institut Armand-Frappier, Institut National de la Recherche Scientifique, Laval, Canada.
2
Institut National de la Transfusion Sanguine, Paris, France.
3
INRS-Institut Armand-Frappier, Institut National de la Recherche Scientifique, Laval, Canada. Electronic address: patrick.labonte@iaf.inrs.ca.

Abstract

Worldwide there are approximately 240million individuals chronically infected with the hepatitis B virus (HBV), including 15-20million coinfected with the hepatitis delta virus (HDV). Treatments available today are not fully efficient and often associated to important side effects and development of drug resistance. Targeting the HBV/HDV entry step using preS1-specific lipopeptides appears as a promising strategy to block viral entry for both HBV and HDV (Gripon et al., 2005; Petersen et al., 2008). Recently, the human Sodium Taurocholate Cotransporting Polypeptide (hNTCP) has been identified as a functional, preS1-specific receptor for HBV and HDV. This groundbreaking discovery has opened a very promising avenue for the treatment of chronic HBV and HDV infections. Here we investigated the ability of FDA approved therapeutics with documented inhibitory effect on hNTCP cellular function to impair viral entry using a HDV in vitro infection model based on a hNTCP-expressing Huh7 cell line. We demonstrate the potential of three FDA approved molecules, irbesartan, ezetimibe, and ritonavir, to alter HDV infection in vitro.

KEYWORDS:

Antivirals; FDA approved therapeutics; Hepatitis B virus; Hepatitis delta virus; Infection; hNTCP

PMID:
24717262
DOI:
10.1016/j.antiviral.2014.03.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center